The University of Chicago Header Logo

Connection

Jessica Donington to Lung Neoplasms

Back to Details
This is a "connection" page, showing publications Jessica Donington has written about Lung Neoplasms.
Jessica Donington
Connection Strength
12.947
Lung Neoplasms
  1. Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2024 Jul; 25(5):440-448.
    View in: PubMed
    Score: 0.382
  2. Event-free survival as a predictor of overall survival and recurrence burden of patients with non-small cell lung cancer receiving neoadjuvant therapy. J Thorac Cardiovasc Surg. 2024 Oct; 168(4):1261-1269.e1.
    View in: PubMed
    Score: 0.375
  3. Current Management of Stage IIIA (N2) Non-Small-Cell Lung Cancer: Role of Perioperative Immunotherapy, and Tyrosine Kinase Inhibitors. Thorac Surg Clin. 2023 May; 33(2):189-196.
    View in: PubMed
    Score: 0.355
  4. Oncologic end points and implication of trial design in the era of immunotherapy for resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 06; 165(6):1949-1953.
    View in: PubMed
    Score: 0.347
  5. Lung resection surgery in Jehovah's Witness patients: a 20-year single-center experience. J Cardiothorac Surg. 2022 Oct 20; 17(1):272.
    View in: PubMed
    Score: 0.346
  6. Integration of New Systemic Adjuvant Therapies for Non-small Cell Lung Cancer: Role of the Surgeon. Ann Thorac Surg. 2023 06; 115(6):1544-1555.
    View in: PubMed
    Score: 0.345
  7. Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer: Exciting New Horizon in Early-Stage Lung Cancer Care. Ann Surg Oncol. 2022 09; 29(9):5344-5346.
    View in: PubMed
    Score: 0.337
  8. The Increasing Role of Surgery in Comprehensive Treatment of Advanced Non-small Cell Lung Cancer with Targetable Mutations. Ann Surg Oncol. 2022 08; 29(8):4679-4680.
    View in: PubMed
    Score: 0.335
  9. Surgical Issues for Operable Early-Stage Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 02 20; 40(6):530-538.
    View in: PubMed
    Score: 0.328
  10. Commentary: Why do we operate in metastatic lung cancer? J Thorac Cardiovasc Surg. 2022 03; 163(3):826-827.
    View in: PubMed
    Score: 0.313
  11. Resection following concurrent chemotherapy and high-dose radiation for stage IIIA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2020 11; 160(5):1331-1345.e1.
    View in: PubMed
    Score: 0.293
  12. Lung Cancer: Advances in Diagnosis and Management. Semin Respir Crit Care Med. 2020 Jun; 41(3):333-334.
    View in: PubMed
    Score: 0.293
  13. Update on Lung Cancer Screening. Semin Respir Crit Care Med. 2020 Jun; 41(3):447-452.
    View in: PubMed
    Score: 0.293
  14. Commentary: Why does neoadjuvant therapy suddenly make sense for early stage non-small cell lung cancer? J Thorac Cardiovasc Surg. 2020 11; 160(5):1383-1384.
    View in: PubMed
    Score: 0.291
  15. Commentary: The need to RIOT (return to intended oncologic treatment) after lung cancer surgery. J Thorac Cardiovasc Surg. 2019 07; 158(1):287-288.
    View in: PubMed
    Score: 0.272
  16. The Role of Surgery in Management of Locally Advanced Non-Small Cell Lung Cancer. Curr Treat Options Oncol. 2019 03 14; 20(4):27.
    View in: PubMed
    Score: 0.270
  17. Early-Stage NSCLC: Advances in Thoracic Oncology 2018. J Thorac Oncol. 2019 06; 14(6):968-978.
    View in: PubMed
    Score: 0.269
  18. Commentary: Keeping surgery relevant in oligometastatic non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019 04; 157(4):1629-1630.
    View in: PubMed
    Score: 0.263
  19. Thoracotomy for Stage I Lung Cancer Resections: A Procedure Past Its Time. J Clin Oncol. 2018 08 10; 36(23):2361-2362.
    View in: PubMed
    Score: 0.257
  20. Progress in the Management of Early-Stage Non-Small Cell Lung Cancer in 2017. J Thorac Oncol. 2018 06; 13(6):767-778.
    View in: PubMed
    Score: 0.253
  21. Making computed tomographic screening accessible for all. J Thorac Cardiovasc Surg. 2018 06; 155(6):2682.
    View in: PubMed
    Score: 0.249
  22. Surgical Treatment of Early l Stage Lung Cancer: What has Changed and What will Change in the Future. Semin Respir Crit Care Med. 2016 10; 37(5):708-715.
    View in: PubMed
    Score: 0.228
  23. Sublobar Resection: Ongoing Controversy for Treatment for Stage I Non-Small Cell Lung Cancer. Thorac Surg Clin. 2016 Aug; 26(3):251-9.
    View in: PubMed
    Score: 0.225
  24. An Additional Step Toward Personalization of Surgical Care for Early-Stage Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Feb 01; 34(4):295-6.
    View in: PubMed
    Score: 0.215
  25. Survival After Sublobar Resection Versus Lobectomy for Clinical Stage IA Lung Cancer: Analysis From the National Cancer Database. J Thorac Oncol. 2015 Nov; 10(11):1513-4.
    View in: PubMed
    Score: 0.214
  26. Radiofrequency ablation in high-risk stage I non-small cell lung cancer. Cancer. 2015 Oct 01; 121(19):3393-4.
    View in: PubMed
    Score: 0.208
  27. Surgical resection of non-small cell lung cancer with N2 disease. Thorac Surg Clin. 2014 Nov; 24(4):449-56.
    View in: PubMed
    Score: 0.197
  28. Managing lung cancer in high-risk patients: what to consider. Expert Rev Respir Med. 2014 Aug; 8(4):443-52.
    View in: PubMed
    Score: 0.194
  29. Invited commentary. Ann Thorac Surg. 2013 Dec; 96(6):1951.
    View in: PubMed
    Score: 0.187
  30. Surgical approach to locally advanced non-small cell lung cancer. Cancer J. 2013 May-Jun; 19(3):217-21.
    View in: PubMed
    Score: 0.180
  31. Invited commentary. Ann Thorac Surg. 2013 Feb; 95(2):418-9.
    View in: PubMed
    Score: 0.177
  32. Current readings: sublobar resection for non-small-cell lung cancer. Semin Thorac Cardiovasc Surg. 2013; 25(1):22-9.
    View in: PubMed
    Score: 0.176
  33. Point: are limited resections appropriate in non-small cell lung cancer? Yes. Chest. 2012 Mar; 141(3):588-590.
    View in: PubMed
    Score: 0.166
  34. Invited commentary. Ann Thorac Surg. 2012 Feb; 93(2):403-4.
    View in: PubMed
    Score: 0.165
  35. Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population. Cancer Biomark. 2012; 12(4):177-84.
    View in: PubMed
    Score: 0.164
  36. Management of early stage non-small cell lung cancer in high-risk patients. Thorac Surg Clin. 2012 Feb; 22(1):55-65, vi.
    View in: PubMed
    Score: 0.162
  37. Invited commentary. Ann Thorac Surg. 2011 Jul; 92(1):250.
    View in: PubMed
    Score: 0.158
  38. Novel therapies for non-small cell lung cancer. J Thorac Imaging. 2011 May; 26(2):175-85.
    View in: PubMed
    Score: 0.156
  39. Sex and gender differences in non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2011; 23(2):137-45.
    View in: PubMed
    Score: 0.153
  40. Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Thorac Oncol. 2010 Oct; 5(10):1516-23.
    View in: PubMed
    Score: 0.150
  41. Sublobar resection: a movement from the Lung Cancer Study Group. J Thorac Oncol. 2010 Oct; 5(10):1583-93.
    View in: PubMed
    Score: 0.150
  42. Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol. 2010 Feb 20; 28(6):936-41.
    View in: PubMed
    Score: 0.143
  43. Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thorac Cardiovasc Surg. 2010 Jun; 139(6):1587-93.
    View in: PubMed
    Score: 0.140
  44. The role of surgery in the treatment of stage III non-small-cell lung cancer. Curr Oncol Rep. 2007 Jul; 9(4):247-54.
    View in: PubMed
    Score: 0.120
  45. Management of locally advanced non small cell lung cancer from a surgical perspective. Curr Treat Options Oncol. 2007 Feb; 8(1):1-14.
    View in: PubMed
    Score: 0.116
  46. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol. 2006 Oct; 1(8):802-9.
    View in: PubMed
    Score: 0.114
  47. Lung cancer in women: exploring sex differences in susceptibility, biology, and therapeutic response. Clin Lung Cancer. 2006 Jul; 8(1):22-9.
    View in: PubMed
    Score: 0.112
  48. American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2024 Jun 01; 10(6):799-806.
    View in: PubMed
    Score: 0.097
  49. Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility. J Clin Oncol. 2024 Jun 10; 42(17):2026-2037.
    View in: PubMed
    Score: 0.096
  50. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revisions of the T-Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024 May; 19(5):749-765.
    View in: PubMed
    Score: 0.094
  51. Treatment Decisions for Resectable Non-Small-Cell Lung Cancer: Balancing Less With More? Am Soc Clin Oncol Educ Book. 2023 May; 43:e389950.
    View in: PubMed
    Score: 0.090
  52. STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023 01; 7:e2200273.
    View in: PubMed
    Score: 0.088
  53. Impact of Federal Lung Cancer Screening Policy on the Incidence of Early-stage Lung Cancer. Ann Thorac Surg. 2023 04; 115(4):827-833.
    View in: PubMed
    Score: 0.087
  54. Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy. J Thorac Oncol. 2022 09; 17(9):1130-1136.
    View in: PubMed
    Score: 0.085
  55. Subsequent pulmonary resection for bronchogenic carcinoma after pneumonectomy. Ann Thorac Surg. 2002 Jul; 74(1):154-8; discussion 158-9.
    View in: PubMed
    Score: 0.085
  56. Consensus for Thoracoscopic Lower Lobectomy: Essential Components and Targets for Simulation. Ann Thorac Surg. 2022 11; 114(5):1895-1901.
    View in: PubMed
    Score: 0.081
  57. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
    View in: PubMed
    Score: 0.081
  58. American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):361-375.
    View in: PubMed
    Score: 0.080
  59. American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020. J Thorac Oncol. 2021 01; 16(1):66-75.
    View in: PubMed
    Score: 0.076
  60. American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC. J Thorac Oncol. 2021 01; 16(1):54-65.
    View in: PubMed
    Score: 0.075
  61. The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer. J Thorac Oncol. 2020 03; 15(3):344-359.
    View in: PubMed
    Score: 0.071
  62. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol. 2018 03 20; 36(9):911-919.
    View in: PubMed
    Score: 0.062
  63. The value of collaboration between thoracic surgeons and radiation oncologists while awaiting evidence in operable stage i non-small cell lung cancer. J Thorac Cardiovasc Surg. 2018 Jan; 155(1):429-431.
    View in: PubMed
    Score: 0.062
  64. Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839. J Thorac Oncol. 2017 09; 12(9):1413-1420.
    View in: PubMed
    Score: 0.060
  65. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017 Sep - Oct; 7(5):295-301.
    View in: PubMed
    Score: 0.060
  66. Salvage Resections for Stage III Non-small Cell Lung Cancer: A Curious Area of Investigation. Semin Thorac Cardiovasc Surg. 2017; 29(2):242-243.
    View in: PubMed
    Score: 0.059
  67. The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification. J Thorac Oncol. 2016 05; 11(5):666-680.
    View in: PubMed
    Score: 0.055
  68. The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. J Thorac Oncol. 2016 05; 11(5):639-650.
    View in: PubMed
    Score: 0.055
  69. The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016 05; 11(5):681-692.
    View in: PubMed
    Score: 0.055
  70. The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016 05; 11(5):651-665.
    View in: PubMed
    Score: 0.055
  71. Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. J Thorac Oncol. 2016 06; 11(6):900-9.
    View in: PubMed
    Score: 0.055
  72. Overexpression of EPH receptor B2 in malignant mesothelioma correlates with oncogenic behavior. J Thorac Oncol. 2013 Sep; 8(9):1203-11.
    View in: PubMed
    Score: 0.046
  73. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May; 143(5 Suppl):e93S-e120S.
    View in: PubMed
    Score: 0.045
  74. Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer. Clin Lung Cancer. 2011 Sep; 12(5):280-5.
    View in: PubMed
    Score: 0.040
  75. Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer. J Thorac Oncol. 2011 May; 6(5):920-6.
    View in: PubMed
    Score: 0.039
  76. Initial experience with endobronchial ultrasound in an academic thoracic surgery program. Clin Lung Cancer. 2010 Jan; 11(1):25-9.
    View in: PubMed
    Score: 0.036
  77. Complications of ablative therapies in lung cancer. Clin Lung Cancer. 2008 Mar; 9(2):122-6.
    View in: PubMed
    Score: 0.031
  78. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007 Oct 01; 69(2):328-33.
    View in: PubMed
    Score: 0.030
  79. Recurrence of pulmonary intravascular bronchoalveolar tumor with mediastinal metastasis 20 years later. Respir Med. 2006 Feb; 100(2):367-70.
    View in: PubMed
    Score: 0.026
  80. Hamartomas of the lung. Semin Thorac Cardiovasc Surg. 2003 Jul; 15(3):301-4.
    View in: PubMed
    Score: 0.023
  81. Consensus for Thoracoscopic Left Upper Lobectomy-Essential Components and Targets for Simulation. Ann Thorac Surg. 2021 08; 112(2):436-442.
    View in: PubMed
    Score: 0.019
  82. Isolated lung perfusion with tumor necrosis factor for pulmonary metastases. Ann Thorac Surg. 1996 Jun; 61(6):1609-17.
    View in: PubMed
    Score: 0.014
  83. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006 Mar 01; 12(5):1507-14.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.